Get the Daily Brief
Latest Biotech News
Ferroptosis and iron handling biology surfaces as drug target terrain
New lab findings are tightening the mechanistic link between iron metabolism and ferroptosis, increasing the number of actionable nodes for drug discovery. A study in Experimental & Molecular...
Phase 3 lymphoma safety signals roil Zynlonta’s path to full approval
ADC Therapeutics’ confirmatory Phase 3 LOTIS-5 dataset for Zynlonta (polatuzumab vedotin?—as described in the provided text: Zynlonta plus rituximab) has raised serious safety concerns and...
Germany austerity pressures big pharma manufacturing plans
Eli Lilly and Boehringer Ingelheim have rolled back large-scale investments in Germany in response to proposed health spending cuts. According to Handelsblatt reporting carried in the provided...
Russia? (Federal) 340B compliance squeeze tightens around Lilly
Eli Lilly has escalated enforcement of its 340B claims data policy, issuing an ultimatum to hospitals that have not complied with requests to share data intended to show they are not...
AI-for-RNA drug discovery cashes in: Alnylam and Inceptive expand to up-to-$2B
Alnylam has signed a multi-year AI-enabled RNA discovery collaboration with Inceptive Nucleics, with total potential value described as up to $2 billion. The deal structure includes $30 million...
Longevity biotech NewLimit bets big ahead of first-in-human liver age reprogramming trial
NewLimit has raised $435 million in a Series C financing to advance its first-in-human cell age reprogramming therapy targeting liver cells. The company’s stated plans are to start Phase I...
RNA exon editing gets a Lilly-sized vote of confidence in inherited kidney disease
Eli Lilly has entered a global research and licensing collaboration with Ascidian Therapeutics centered on RNA exon editing for monogenic inherited kidney diseases. Under the reported structure,...
Precision oncology platform partnerships move toward clinical implementation
Diagnostics and sequencing platforms are continuing to push deeper into clinical workflows, with partnerships aimed at making whole-genome sequencing and AI-driven cancer analysis more “default”...
Diagnostics and imaging advances: FDA nod for mold cfDNA and faster cardiac valve assessment
Diagnostic innovation moved on two fronts, with one regulatory milestone and one translational imaging advance. The FDA granted Zepto Life Technologies breakthrough device designation for its...
Longevity cell-age reprogramming
NewLimit, the aging-biotech backed by investors including Founders Fund, Thrive Capital, and Lilly Ventures, raised $435 million in a Series C to fund its first-in-human cell age reprogramming...
Alnylam inks AI deal with Inceptive Nucleics
Alnylam agreed a three-year, up-to-$2 billion strategic collaboration with Inceptive Nucleics, the AI startup co-founded by Jakob Uszkoreit, creator of the transformer architecture behind ChatGPT....
Cancer – pan-RAS inhibitor daraxonrasib extends survival
Revolution Medicines’ pan-RAS inhibitor daraxonrasib posted phase 3 results that nearly doubled overall survival in metastatic pancreatic ductal adenocarcinoma versus investigator-selected...
Regenerative and advanced cell therapy manufacturing
Cabaletta is pushing a CAR-T approach in autoimmune disease that it says could reduce or eliminate chemotherapy preconditioning. At EULAR 2026, the company described early patient updates...
Precision diagnostics – European IVDR certification for cancer syndromes
MRC Holland received CE-IVDR certification for the SALSA MLPA Probemix P008 PMS2 assay, a blood-based test for cancer-predisposition conditions linked to PMS2. The assay detects deletions and...
Oncology biotech funding – Ona Therapeutics raises for ADCs
Ona Therapeutics closed an oversubscribed $86.6 million Series B to advance two antibody-drug conjugates into human testing. The Barcelona-based biotech will use the funds primarily to push...
Cell therapy manufacturing scale-up – TSC-101 automation deal
Cellares and TScan Therapeutics agreed to evaluate automated manufacturing of TSC-101, TScan’s lead TCR-T therapy candidate for acute myeloid leukemia and myelodysplastic syndromes in the...
Gene therapy diagnostics – FDA breakthrough for invasive mold cfDNA panel
The FDA granted Zepto Life Technology breakthrough device designation for its FungiFlex Mold Panel, a blood-based diagnostic that aims to detect and distinguish circulating cell-free DNA from...
Aging and liver disease therapeutics – regulatory/clinical pipeline move
NewLimit’s funding and clinical plan places cell-age reprogramming directly into the liver disease pipeline, with early enrollment for fatty liver disease. The approach targets aging biology at...
Oncology drug efficacy and phase 3 readouts
Revolution Medicines’ pan-RAS inhibitor daraxonrasib delivered a major survival gain in phase 3 RASolute 302 for advanced pancreatic ductal adenocarcinoma, nearly doubling median survival versus...
ADC pipeline funding momentum
Ona Therapeutics raised $86.6 million in an oversubscribed Series B to advance two antibody-drug conjugates into human testing. The Barcelona-based biotech will prioritize clinical advancement of...